SMA Peg denied due to quantity / dose limits by Anthem?

Anthem's specific coverage criteria for sma peg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Limits Quantities for Pegylated SMA Therapy — and Why You Can Fight Back

Quantity-limit denials for pegylated therapies used in spinal muscular atrophy (SMA) management are among the most common coverage disputes Anthem members face. Insurers impose these limits primarily for cost-management reasons, often setting thresholds below what a prescriber deems clinically appropriate for a specific patient's weight, functional status, or disease trajectory. The limit cited in your denial letter is Anthem's internal policy figure — it is not derived from the FDA-approved prescribing label, and your prescriber's judgment about the medically necessary quantity has equal standing in an appeal.

## The Federal Appeal Framework

You have layered federal protections:

• Internal appeal (Level 1): Submit within the timeframe shown on your denial notice (typically 180 days for ERISA plans). Anthem must decide within 30 days for pre-service and 60 days for post-service claims.
• External review (ACA §2719): If Anthem upholds the denial, you may request an independent external review. For most employer-sponsored and ACA-marketplace plans this window is approximately 4 months (120 days) from the final internal denial. An independent review organization — not Anthem — makes the binding decision.
• Expedited review: If a delay would seriously jeopardize your health, request expedited review in writing simultaneously with your internal appeal. Anthem must respond within 72 hours.
• ERISA §503 (employer plans): Grants you the right to a full-and-fair review of all evidence, including the specific criteria used to set the quantity limit.

## What to Gather

1. Diagnosis confirmation — neurology or neuromuscular specialist notes confirming SMA type, functional classification, and disease progression. 2. Prescriber medical-necessity letter — your physician should state, in writing, why the prescribed quantity is medically necessary for your body weight, dosing interval, and clinical circumstances, citing the FDA-approved prescribing label's dosing framework. 3. Prior treatment history — dates, doses attempted, and documented outcomes or tolerability issues for any prior SMA therapies. 4. Clinical severity documentation — motor function assessments, respiratory function data, and any validated functional scales recorded in your chart. 5. The FDA label — obtain the current prescribing information for the specific pegylated SMA therapy and note the approved dosing range for your patient population.

## Criteria-Mapping Structure

Copy each requirement from Anthem's published medical/coverage policy (available on anthem.com or by written request) and pair it with the exact chart evidence that satisfies it:

| Policy Requirement | Supporting Chart Evidence | |---|---| | Confirmed SMA diagnosis | Genetic testing result, specialist note | | Appropriate functional classification | Motor assessment score, dated clinic note | | Quantity within label-approved range | FDA prescribing label excerpt, prescriber calculation | | Prescriber specialty requirement | Treating physician's credentials |

Your appeal should argue that Anthem's internal quantity limit is more restrictive than the FDA-approved label without clinical justification, and that the prescribed quantity is supported by the label's own dosing guidance for your specific characteristics. Attach the label excerpt side-by-side with your prescriber's calculation.